Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Mult Scler Relat Disord
; 45: 102442, 2020 Oct.
Article
em En
| MEDLINE
| ID: mdl-32777745
ABSTRACT
BACKGROUND:
Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).OBJECTIVES:
to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.METHODS:
Case series.RESULTS:
Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.CONCLUSION:
Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Hospedeiro Imunocomprometido
/
Infecções por Coronavirus
/
Anticorpos Monoclonais Humanizados
/
Fatores Imunológicos
/
Esclerose Múltipla
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article